Triamcinolone Acetonide

Introduction Overview

Generic Name

Brand Name

Kenalog

Dosage Form

Injectable suspension

Drug Class

Adrenals (Glucocorticoid)

Pharmacokinetics

Absorption:
Triamcinolone acetonide exhibits distinct absorption profiles depending on the route of administration. After intramuscular (IM) injection of a single 40–80 mg dose, suppression of the hypothalamic-pituitary-adrenal (HPA) axis can persist for 2 to 4 weeks, indicating prolonged systemic availability. When administered orally in a single 40 mg dose, HPA-axis suppression duration is considerably shorter, averaging about 2.25 days. Intra-articular administration delivers localized anti-inflammatory effects that may last several weeks, reflecting slow systemic absorption and prolonged residence at the inflamed site. The variability in absorption and duration is influenced by the formulation, site of injection, and patient-specific factors such as muscle mass or joint pathology.

Distribution:
Once absorbed, triamcinolone acetonide distributes widely throughout the body, rapidly moving from the plasma into tissues including muscles, liver, skin, intestines, and kidneys, reflecting typical glucocorticoid tissue affinities. It crosses physiologic barriers, including the placenta, posing potential risks in pregnancy, and is secreted into breast milk, necessitating caution during lactation. The drug exhibits lower affinity for plasma transcortin (corticosteroid-binding globulin) compared to prednisolone, impacting its free active fraction and pharmacodynamic profile. Distribution volume and tissue binding vary among patients, influenced by factors such as plasma protein levels and disease states.

Metabolism:
Triamcinolone acetonide undergoes hepatic metabolism primarily by cytochrome P450 3A4 (CYP3A4) isoenzymes. This enzymatic pathway transforms the parent compound into inactive metabolites, facilitating systemic clearance. Co-administration of CYP3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics) can elevate plasma levels, increasing glucocorticoid-related adverse effects, while inducers (e.g., rifampin, phenytoin, carbamazepine) may reduce therapeutic efficacy by accelerating metabolism. The metabolic rate may be modified by hepatic impairment or genetic polymorphisms affecting CYP3A4 activity. Monitoring and dosage adjustments are warranted in polypharmacy contexts or altered liver function.

Elimination:
Elimination of triamcinolone acetonide metabolites occurs predominantly through renal excretion, with a minor proportion eliminated via feces. The pharmacokinetic elimination half-life varies by route; systemic clearance is prolonged following IM administration due to a depot effect from the suspension form, leading to sustained systemic exposure. Intra-articular injections provide localized effects with minimal systemic elimination initially, but eventual resorption leads to systemic metabolism and clearance. Renal impairment may slow elimination, increasing the risk of accumulation and side effects, emphasizing caution in affected patients. Dose titration and monitoring remain essential to balance efficacy with safety.

Dosage Forms

Available Dosage Forms:
Triamcinolone acetonide is commercially available exclusively as a parenteral injectable suspension under the brand name Kenalog. The suspension is provided in three strengths:
- 10 mg/mL injectable suspension
- 40 mg/mL injectable suspension
- 80 mg/mL injectable suspension
All formulations are sterile suspensions intended for intramuscular or localized injections, depending on the specific indication.

Dosages for Adults and Adolescents:
- Intramuscular (IM) Injection: Typically, adults receive an initial dose of 40 to 80 mg administered deep into the gluteal muscle. Subsequent doses ranging from 20 to 100 mg may be administered based on clinical response and recurrence of symptoms. IM injections are recommended at intervals of approximately 6 weeks to minimize hypothalamic-pituitary-adrenal (HPA) axis suppression.
- Intra-articular, Intrabursal, Intrasynovial, or Soft-Tissue Injection: Dosage depends on the size and inflammation severity of the joint or soft tissue. Large joints usually receive 5 to 15 mg per injection, small joints receive 2.5 to 5 mg, and tendon sheath inflammation may be treated with 2.5 to 10 mg. Symptom relief generally occurs with dosages not exceeding 40 mg for large joints and 10 mg for small joints. Re-administration is performed as needed.
- Intralesional or Sublesional Injection: The 10 mg/mL suspension is preferred for intralesional use, with multiple injection sites permitted if spaced at least 1 cm apart. Total dosage should not exceed 30 mg in a single treatment session.

Specific Patient Populations:
- Pediatric Patients: Dosage is individualized based on disease severity and response rather than strict guidelines. Initial IM doses range from 0.11 mg/kg daily up to 1.6 mg/kg daily in 3 or 4 divided doses (equivalent to 3.2 mg/m² to 48 mg/m² body surface area per day).
- Geriatric Patients: Dosages generally follow adult guidelines but warrant caution due to increased risk of glucocorticoid-induced complications such as osteoporosis and muscle wasting.
- Renal and Hepatic Impairment: Use with caution; dose adjustments may be necessary based on clinical response and side effects.

Storage and Handling:
Triamcinolone acetonide injectable suspensions should be stored at controlled room temperature (20–25°C), protected from freezing and light. Vials must be shaken thoroughly before use to ensure uniform suspension of the particles for accurate dosing. The 10 mg/mL formulation is not intended for IM injection, reserved for intralesional or local soft tissue administration.

Mechanism Of Action

Triamcinolone acetonide is a synthetic glucocorticoid derivative that exerts potent anti-inflammatory and immunosuppressive effects with minimal mineralocorticoid activity. Its primary mechanism involves binding to the cytoplasmic glucocorticoid receptor (GR), leading to receptor activation and translocation into the nucleus where it modulates gene transcription. By activating glucocorticoid response elements (GREs), triamcinolone induces the expression of anti-inflammatory proteins such as lipocortin-1, which inhibits phospholipase A2, thereby reducing the release of arachidonic acid and subsequent synthesis of pro-inflammatory mediators including prostaglandins and leukotrienes.

At the cellular level, triamcinolone decreases leukocyte infiltration by suppressing adhesion molecules on endothelial cells, thereby limiting leukocyte migration into inflamed tissues. It also stabilizes lysosomal membranes of neutrophils and macrophages, preventing the release of destructive enzymes and reducing tissue damage. Additionally, it diminishes capillary permeability and edema formation by counteracting histamine and kinin effects, contributing to the reduction of swelling and redness in inflamed areas.

The drug also inhibits macrophage accumulation at sites of inflammation and suppresses fibroblast proliferation and collagen deposition, moderating scar tissue formation during the healing process. Immunologically, triamcinolone suppresses humoral and cell-mediated immune responses by reducing lymphocyte populations, particularly T-helper cells, and decreasing immunoglobulin and complement protein synthesis. This immunosuppressive action is critical in treating autoimmune and hypersensitivity disorders.

Compared to other glucocorticoids such as prednisone or methylprednisolone, triamcinolone has a relatively longer duration of action and negligible mineralocorticoid effects, which makes it favorable in conditions where fluid retention is undesirable. Clinical studies demonstrate its efficacy in controlling acute and chronic inflammatory conditions, with research highlighting its role in modulating key transcription factors like NF-κB and AP-1. These molecular interactions underpin its broad therapeutic application in inflammatory, allergic, hematologic, and autoimmune diseases.

Pharmacological Actions

Potent anti-inflammatory glucocorticoid activity with virtually no mineralocorticoid effects.
Stabilization of leukocyte lysosomal membranes to prevent enzymatic tissue damage.
Inhibition of phospholipase A2 activity, reducing synthesis of prostaglandins and leukotrienes.
Suppression of leukocyte adhesion and migration to sites of inflammation.
Reduction of capillary permeability and edema formation by antagonizing histamine and kinins.
Inhibition of macrophage accumulation in inflamed tissues.
Suppression of fibroblast proliferation and collagen deposition, reducing scar formation.
Immunosuppression via lymphocytopenia, decreased immunoglobulin production, and complement inhibition.
Stimulation of erythroid bone marrow cells, prolonging erythrocyte and platelet lifespan.
Promotion of gluconeogenesis, fat redistribution, and protein catabolism leading to negative nitrogen balance.
Reduction of intestinal calcium absorption with increased renal calcium excretion.
Depression of tissue reactivity to antigen-antibody interactions.
Prolonged systemic effects following IM or intra-articular administration due to slow absorption.
Modulation of gene expression via glucocorticoid receptor interactions influencing inflammatory pathways.
Reduction in systemic and localized inflammatory responses across multiple organ systems.

Therapeutic Or Clinical Uses

Treatment of diverse inflammatory and autoimmune disorders including rheumatoid arthritis, systemic lupus erythematosus, and vasculitis.
Management of adrenocortical insufficiency as glucocorticoid replacement therapy in conjunction with mineralocorticoids.
Palliative treatment of hematologic disorders such as autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, and congenital hypoplastic anemia.
Control of dermatologic diseases including severe eczema, psoriasis, pemphigus, pemphigoid, lichen planus, and cutaneous sarcoidosis.
Treatment of allergic manifestations such as severe seasonal/perennial rhinitis, serum sickness, and drug hypersensitivity reactions.
Therapy for ocular inflammatory conditions like allergic conjunctivitis, uveitis, iritis, and keratitis.
Management of hypercalcemia secondary to malignancy, sarcoidosis, or vitamin D intoxication.
Adjunctive treatment in neoplastic disorders including leukemias and lymphomas.
Control of inflammatory bowel diseases during acute exacerbations including ulcerative colitis and Crohn’s disease.
Symptomatic relief in musculoskeletal conditions such as gouty arthritis, tendinitis, bursitis, and ankylosing spondylitis.
Prevention of organ transplant rejection in combination with other immunosuppressants.
Treatment of nephrotic syndrome and lupus nephritis to induce remission and reduce proteinuria.
Local injection for carpal tunnel syndrome to relieve pain and swelling.
Management of sarcoidosis with severe systemic involvement or refractory skin lesions.
Treatment of granulomatous thyroiditis and orbital edema associated with thyroid ophthalmopathy.

Side Or Adverse Effects

Suppression of adrenal axis leading to secondary adrenal insufficiency upon abrupt withdrawal.
Increased susceptibility to infections including bacterial, viral, fungal, and parasitic etiologies.
Muscle wasting, myopathy, and protein catabolism leading to weakness.
Osteoporosis with increased risk of vertebral compression and pathological fractures.
Delayed wound healing and skin atrophy.
Development of posterior subcapsular cataracts and elevated intraocular pressure with potential glaucoma.
Psychiatric disturbances ranging from mood swings and anxiety to psychosis.
Hyperglycemia and exacerbation or precipitation of diabetes mellitus.
Fluid retention, hypertension, and potential exacerbation of congestive heart failure.
Gastrointestinal ulceration and increased risk of gastrointestinal bleeding.
Electrolyte disturbances including hypokalemia potentiated by concomitant potassium-wasting drugs.
Growth retardation and decreased growth velocity in pediatric patients.
Potential anaphylaxis or severe hypersensitivity reactions to injectable formulations.
Cushingoid features such as moon face, central obesity, and facial erythema with chronic use.
Transient blindness and neurologic events reported after epidural administration.

Precautions

Careful monitoring for HPA-axis suppression, especially during long-term therapy.
Avoid abrupt discontinuation; taper dosage gradually to prevent withdrawal symptoms.
Screen and monitor for latent or active infections prior to and during therapy.
Use caution in patients with diabetes mellitus due to effects on glucose metabolism.
Monitor intraocular pressure to detect early onset of glaucoma or cataracts.
Use cautiously in patients with hypertension, congestive heart failure, or thromboembolic disorders.
Assess risk-benefit in pediatric patients with attention to growth and development impacts.
Avoid IM administration in patients with bleeding disorders like idiopathic thrombocytopenic purpura.
Use caution with concurrent administration of CYP3A4 inhibitors or inducers that alter metabolism.
Ensure appropriate immunization status and avoid live vaccines during immunosuppressive dosing.
Adjust dosage and monitor closely in hepatic or renal impairment.
Avoid use in patients with active ocular herpes simplex infection due to risk of corneal perforation.
Prevent exposure to varicella and measles in susceptible individuals on immunosuppressive therapy.
Administer with caution in patients with known psychiatric disorders.
Evaluate for potential drug interactions that may alter corticosteroid efficacy or toxicity.

Warnings

Epidural glucocorticoid injections have been associated with serious neurologic events, including spinal cord infarction and paralysis; use only with thorough risk assessment.
Prolonged systemic corticosteroid therapy can cause adrenal suppression and life-threatening adrenal crisis during stress if withdrawn abruptly.
Immunosuppressed patients are at increased risk for severe infections, some potentially fatal.
High-dose or long-term therapy can cause osteoporosis, muscle atrophy, and pathologic fractures.
Use may precipitate or exacerbate psychiatric disturbances including psychosis, anxiety, and mood swings.
Glucocorticoids may mask signs of infection and delay diagnosis or appropriate treatment.
Patients with diabetes or impaired glucose tolerance require close glucose monitoring due to risk of hyperglycemia.
Systemic corticosteroids may impair growth and development in pediatric patients.
Corticosteroids can increase coagulability and risk of thrombosis; exercise caution in thromboembolic disorders.
Potential for increased intraocular pressure leading to glaucoma; ophthalmologic evaluation recommended.
Do not administer live virus vaccines during immunosuppressive corticosteroid therapy due to risk of vaccine-related infection.
Use caution in patients with hepatic or renal impairment due to altered pharmacodynamics and risk of toxicity.
May exacerbate hypertension or congestive heart failure; monitor cardiovascular status carefully.
Careful assessment needed before use in pregnancy; potential teratogenicity noted in animal studies.
Possibility of severe allergic reactions including anaphylaxis has been reported; have emergency measures available.

Contraindication

Known hypersensitivity to triamcinolone acetonide or any component of the formulation.
Intramuscular injection in patients with idiopathic thrombocytopenic purpura due to bleeding risk.
Concurrent administration of live virus vaccines in patients receiving immunosuppressive doses of corticosteroids.
Use in patients with systemic fungal infections unless combined with appropriate antifungal therapy.
Ocular administration in active ocular herpes simplex infection due to risk of corneal damage.
Patients with untreated systemic tuberculosis unless receiving concurrent anti-tuberculous therapy.
Use contraindicated if hypersensitivity reactions have previously occurred with corticosteroids.
Avoid intra-articular injection into infected joints or tissues.
Use cautiously or avoid during pregnancy unless benefits outweigh potential fetal risk.
Contraindicated for intravenous administration; formulations are intended for IM or local injection only.
Contraindicated in patients who have received recent live vaccines when on immunosuppressive doses.
Known hypersensitivity or idiosyncrasy to benzyl alcohol preservative in neonates.
Contraindicated in patients with systemic viral infections unless adequately controlled.
Avoid use in patients with hypersensitivity to any corticosteroid to prevent anaphylactic reactions.
Patients with active peptic ulcer disease unless benefits justify risks.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics) increase plasma triamcinolone concentration, raising risk of adverse effects.
CYP3A4 inducers (e.g., rifampin, phenytoin, carbamazepine) enhance triamcinolone metabolism, potentially decreasing efficacy.
Potassium-wasting diuretics and amphotericin B increase risk of hypokalemia when used with triamcinolone.
Oral anticoagulants may have altered effects; coagulation parameters should be closely monitored.
Nonsteroidal anti-inflammatory agents (NSAIDs) may increase risk of gastrointestinal ulceration when combined with corticosteroids.
Serum concentrations of salicylates may be decreased by corticosteroids; adjust dosage carefully.
Phenytoin may increase metabolism of triamcinolone, necessitating dosage increase.
Macrolide antibiotics can inhibit metabolism, increasing triamcinolone levels and toxicity risk.
Live vaccines' efficacy may be diminished and risk of infection increased during systemic corticosteroid therapy.
Antibiotics inducing or inhibiting CYP3A4 can affect triamcinolone plasma levels and clinical effect.
Monitoring required when coadministered with agents affecting electrolyte balance or hepatic enzymes.
Rifampin may accelerate clearance leading to reduced corticosteroid efficacy; dosage adjustments may be needed.
Concurrent use with neuromuscular blocking agents may potentiate muscle weakness or myopathy.
Co-administration with immunosuppressive agents increases risk of infection and requires careful supervision.
Vaccination responses may be inadequate; consider serologic testing and additional immunizations when indicated.

Preparations Of The Drug

Triamcinolone acetonide injectable suspension 10 mg/mL (Kenalog) by Bristol-Myers Squibb; indicated primarily for intra-articular or intralesional use.
Triamcinolone acetonide injectable suspension 40 mg/mL (Kenalog) by Bristol-Myers Squibb; for IM and intra-articular applications.
Triamcinolone acetonide injectable suspension 80 mg/mL (Kenalog) by Bristol-Myers Squibb; intended for deep IM or intra-articular injections.
All preparations require shaking prior to administration to ensure uniform particle suspension.
Vials should be stored at controlled room temperature (20–25°C), protected from freezing and light.
Preservative content such as benzyl alcohol may be present; contraindicated in neonates due to risk of toxicity.
Not intended for intravenous use; designed specifically for intramuscular, intra-articular, intralesional, or soft-tissue injection.
Some formulations are restricted to specific routes: Kenalog-10 for intra-articular or intralesional only, Kenalog-40 and -80 for IM or intra-articular only.
Parenteral doses must be individualized based on clinical condition, response, and tolerability.
Commercial products may vary in excipients; consultation of specific product labeling is recommended for clinical practice.
Preparation handling requires aseptic technique and appropriate injection equipment such as minimum 1.5-inch needles for IM administration.
Variable strengths allow titration of dosage for acute management or chronic conditions requiring maintenance therapy.
Combination with local anesthetics may be performed during intra-articular or soft tissue injections.
Multiple injection sites can be used for intralesional administration provided sites are sufficiently spaced.
Drug shortages and availability may vary regionally; refer to drug shortage resource centers for current status.